Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.
about
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsnab-Paclitaxel for the treatment of breast cancer: an update across treatment settingsAssessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.Serum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
P2860
Brief-exposure to preoperative bevacizumab reveals a TGF-β signature predictive of response in HER2-negative breast cancers.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Brief-exposure to preoperative ...... HER2-negative breast cancers.
@en
Brief-exposure to preoperative ...... HER2-negative breast cancers.
@nl
type
label
Brief-exposure to preoperative ...... HER2-negative breast cancers.
@en
Brief-exposure to preoperative ...... HER2-negative breast cancers.
@nl
prefLabel
Brief-exposure to preoperative ...... HER2-negative breast cancers.
@en
Brief-exposure to preoperative ...... HER2-negative breast cancers.
@nl
P2093
P2860
P356
P1476
Brief-exposure to preoperative ...... HER2-negative breast cancers.
@en
P2093
Ajay Basavanhalli
Angel Janevski
Donald R Lannin
Hannah Gilmore
Kimberly Lezon-Geyda
Kristy L S Miskimen
Lyndsay N Harris
Maysa Abu-Khalaf
Nevenka Dimitrova
Nicole Williams
P2860
P304
P356
10.1002/IJC.29808
P577
2015-08-18T00:00:00Z